Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets

Transfusion

Volumn 51, Issue 5, 2011, Pages 1058-1071

  Vamvakas, Eleftherios C ^a  

^a Edars Sinai Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THROMBOCYTE CONCENTRATE;

ARTICLE; BLEEDING; CLINICAL PRACTICE; DISEASE SEVERITY; HEMOSTASIS; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); THERAPY EFFECT; THROMBOCYTE COUNT; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; TREATMENT INDICATION;

BLOOD PLATELETS; BLOOD PRESERVATION; BLOOD-BORNE PATHOGENS; HEMOSTASIS; HUMANS; PLATELET TRANSFUSION; PLATELETPHERESIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79955659606     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02925.x     Document Type: Article

References (56)

1. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F 4th, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG,. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004; 104: 1534-41. (Pubitemid 39166535)
2. Murphy S, Snyder E, Cable R, Slichter SJ, Strauss RG, McCullough J, Lin JS, Corash L, Conlan MG, SPRINT Study Group. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion 2006; 46: 24-33. (Pubitemid 43381781)
3. Pineda A, McCullough J, Benjamin RJ, Cable R, Strauss RG, Burgstaler E, Porter S, Lin L, Metzel P, Conlan MG, SPRINT Study Group. Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial. Transfusion 2006; 46: 526-71.
4. 111Indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet light. Transfusion 2004; 44: 1732-40. (Pubitemid 39644058)
5. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, Edrich R, Goodrich RP,. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45: 1335-41. (Pubitemid 41647801)
6. McCullough J,. Pathogen inactivation: a new paradigm for blood safety. Transfusion 2007; 47: 2180-4. (Pubitemid 350151216)
7. Klein HG, Anderson D, Bernardi MJ, Cable R, Carey W, Hoch JS, Robitaille N, Sivilotti ML, Smaill F,. Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007; 47: 2338-47. (Pubitemid 350151213)
8. Vamvakas EC, Blajchman MA,. Transfusion-related mortality: the on-going risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009; 113: 3406-17.
9. AuBuchon JP,. Current status of pathogen inactivation methods. ISBT Sci Ser 2010; 5: 125-33.
10. Eder AF, Kennedy JM, Dy BA, Notari EP, Weiss JW, Fang CT, Wagner S, Dodd RY, Benjamin RJ, American Red Cross Regional Blood Centers. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: The American Red Cross experience (2004-2006). Transfusion 2007; 47: 1134-42. (Pubitemid 46934307)
11. Eder AF, Kennedy JM, Dy BA, Notari EP, Skeate R, Bachowski G, Mair DC, Webb JS, Wagner SJ, Dodd RY, Benjamin RJ, The American Red Cross Regional Blood Centers. Limiting and detecting bacterial contamination of apheresis platelets: inlet-line diversion and increased culture volume improve component safety. Transfusion 2009; 49: 1554-63.
12. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S,. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362: 600-13.
13. Osselaer JC, Messe N, Hervig T, Bueno J, Castro E, Espinosa A, Accorsi P, Junge K, Jacquet M, Flament J, Corash L,. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008; 48: 1061-71. (Pubitemid 351793479)
14. Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hidajat M, Barbolla L, Tardivel R, Defoin L, Waller C, Mendel I, Raidot JP, Kandel G, De Menter R, Fabrigli P, Dehenau D, Arroyo JL, Pardon F, Grouezec M, Corral M, Jacquet M, Sundin D, Lin L, Corash L,. An active hemovigilance program characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008; 94: 315-23. (Pubitemid 351535733)
15. The Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010; 50: 2362-75.
16. Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus LC, de Greef GE, Luten M, Huijgens PC, Brand A, van Rhenen DJ, Dutch-Belgian HOVON Cooperative Group. Clinical effectiveness of leukoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150: 209-17.
17. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Klüter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L, euroSPRITE Trial. Transfusion of pooled buffy-coat platelet components prepared with a photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003; 101: 2426-33. (Pubitemid 36302092)
18. Delaney M, Meyer E, Cserti-Gazdewich C, Haspel RL, Lin Y, Morris A, Pavenski K, Dzik WH, Murphy M, Slichter S, Wang G, Dumont LJ, Heddle N,. A systematic assessment of the quality of reporting for platelet transfusion studies. Transfusion 2010; 50: 2135-44.
19. Schrezenmeier H, Seifried E,. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? Vox Sang 2010; 99: 1-15.
20. van der Meer PF, Pietersz RNI, Reesink HW,. Storage of platelets in additive solution up to 12 days with maintenance of good in-vitro quality. Transfusion 2004; 44: 1204-11. (Pubitemid 38989753)
21. deWildt-Eggen J, Gulliksson H,. In-vivo and in-vitro comparison of platelets stored in either synthetic media or plasma. Vox Sang 2003; 84: 256-64. (Pubitemid 36702332)
22. Wagner T, Vetter A, Dimonic N, Guber SE, Helmberg W, Kröll W, Lanzer G, Mayr WR, Neumüller J,. Ultrastructural changes and activation differences in platelet concentrates stored in plasma and additive solution. Transfusion 2002; 42: 719-27.
23. Kerkhoffs JLH, Eikenboom JC, Schipperus MS, van Wordragen-Vlaswinkel RJ, Brand R, Harvey MS, de Vries RR, Barge R, van Rhenen DJ, Brand A,. A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. Blood 2006; 108: 3210-15.
24. van der Meer PF, Pietersz RN, Tiekstra MJ, Huijgens PC, Dekker WJ, Reesink HW,. WBC-reduced platelet concentrates from pooled buffy coats in additive solution: an evaluation of in-vitro and in-vivo measures. Transfusion 2001; 41: 917-22. (Pubitemid 32642764)
25. Turner VS, Mitchell SG, Hawker RJ,. More on the comparison of Plasma-Lyte A and PAS 2 as platelet additive solutions. Transfusion 1996; 36: 1033-4.
26. van Der Meer PF, Kerkhoffs JL, Carvers J, Scharenberg J, de Korte D, Brand A, de Wildt-Eggen J,. In-vitro comparison of platelet storage in plasma and in four platelet additive solutions, and the effect of pathogen reduction: a proposal for an in-vitro rating system. Vox Sang 2010; 98: 517-24.
27. Dijkstra-Tiekstra MJ, Pietersz RN, Hendriks EC, Reesink HW, Huijgens PC,. In-vivo PLT increments after transfusions of WBC-reduced PLT concentrates stored for up to 7 days. Transfusion 2004; 44: 330-6. (Pubitemid 38365507)
28. Hogge DE, Thompson BW, Schiffer CA,. Platelet storage for 7 days in second-generation blood bags. Transfusion 1986; 26: 131-5. (Pubitemid 16139661)
29. Diedrich B, Ringden O, Watz E, Shanwell A,. A randomized study of buffy-coat platelets in platelet additive solution stored 1-5 versus 6-7 days prior to prophylactic transfusion of allogeneic hematopoietic progenitor cell transplant recipients. Vox Sang 2009; 97: 254-9.
30. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, Rodey G, Schiffer CA, Woodson R,. Factors effecting post-transfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105: 4106-14. (Pubitemid 40656162)
31. Klumpp TR, Herman JH, Innis S, Pearlman E, Culling N, Kotz KW, Slachta C, Goldberg SL, Mangan KF,. Factors associated with response to platelet transfusion following hematopoietic stem-cell transplantation. Bone Marrow Transplant 1996; 17: 1035-41. (Pubitemid 26235851)
32. Norol F, Kuentz M, Cordonnier C, Beaujean F, Haiouin C, Vernant JP, Duedari N,. Influence of clinical status on the efficacy of stored platelet transfusion. Br J Hematol 1994; 86: 125-9. (Pubitemid 24194391)
33. Bishop JF, Matthews JP, McGrath K, Yuen K, Wolf MM, Szer J,. Factors influencing 24-hour increments after platelet transfusion. Transfusion 1991; 31: 392-6.
34. Miller AB, Hoogstraten B, Staquet M, Winkler A,. Reporting results of cancer treatment. Cancer 1981; 47: 207-14. (Pubitemid 11167383)
35. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W, Curran W,. Common toxicity criteria version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000; 47: 13-47. (Pubitemid 30179675)
36. Snyder E, McCullough J, Slichter SJ, Strauss RG, Lopez-Plaza I, Lin JS, Corash L, Conlan MG, SPRINT Study Group. Clinical safety of platelets photochemically-treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005; 45: 1864-75. (Pubitemid 43971413)
37. Webert KE, Cook RJ, Sigouin CS, Rebulla P, Heddle NM,. The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica 2006; 91: 1530-7. (Pubitemid 44736120)
38. Heddle NM,. Optimal timing and dosing of platelet transfusions. ISBT Sci Ser 2010; 5: 88-94.
39. Heddle NK, Cook RJ, Tinmouth A, Kouroukis CT, Hervig T, Klapper E, Brandwein JM, Szczepiorkowski ZM, AuBuchon JP, Barty RL, Lee KA, SToP Study Investigators of the BEST Collaborative. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009; 113: 1564-73.
40. Cooper H, Hedges LV, editors. The handbook of research synthesis. New York, NY: Russell Sage Foundation; 1994.
41. Cochran WG,. The combination of estimates from different experiments. Biometrics 1954; 10: 101-29.
42. Yusuf S, Peto R, Lewis J, Collins R, Sleight P,. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-71. (Pubitemid 15107153)
43. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Controlled Clin Trials 1986; 7: 177-88. (Pubitemid 17189972)
44. Janetzko K, Cazenave JP, Kluter H, Kientz D, Michel M, Beris P, Lioure B, Hastka J, Marblie S, Mayaudon V, Lin L, Lin JS, Conlan MG, Flament J,. Therapeutic efficacy and safety of photochemically-treated apheresis platelets processed with an optimized integrated set. Transfusion 2005; 45: 1443-52. (Pubitemid 44194647)
45. Simonsen AC, Johansson PI, Conlan MG, Jacquet M, Lin JS, Junge K, Lin L, SÃrensen H, Borregaard N, Flament J,. Transfusion of 7-day-old amotosalen photochemically-treated buffy-coat platelets to patients with thrombocytopenia: a pilot study. Transfusion 2006; 46: 424-33. (Pubitemid 43334097)
46. Slichter SJ, Raife TJ, Davis K, Rheinschmidt M, Buchholz DH, Corash L, Conlan MG,. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 2006; 46: 731-40.
47. Lozano M, Knutson N, Tardivel R, Cid J, Maymo R, Lof HM, Roddie HP, Pelly JP, Dochery AR, Sherman CD, Lin L, Propst M, Corash L, Prowse CV,. A multicenter study of therapeutic efficacy and safety of platelet components prepared with pathogen inactivation (Intercept) stored for 6-7 days prior to transfusion. Vox Sang 2010; 99 (Suppl 1): 13.
48. Truilzi DJ, Assmann SF, Strauss RG, Ness PM, Hess J, Granger S, Slichter SJ,. The effect of platelet characteristics on the platelet increment and HLA alloimmunization in hypoproliferative thrombocytopenia. Transfusion 2010; 50 (Suppl. 2): 3A.
49. Dumont LJ, Dumont DF, Unger ZM, Siegel A, Szczepiorkowski ZM, Corson JS, Jones M, Christoffel T, Pellham E, Slichter SJ,. A randomized controlled trial comparing autologous radiolabeled in vivo platelet recoveries and survivals of 7-day stored PRP and buffy coat platelets from the same donors. Transfusion 2010; 50 (Suppl 2): 1A.
50. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122: 10-23.
51. TM Introductory Guide. Version 3.3. Reston, VA: MedDRA MSSO; 2002 Dec.
52. Vostal JG, Reid TJ, Mondoro TH,. Summary of a workshop on in-vivo efficacy of transfused platelet components and platelet substitutes. Transfusion 2000; 40: 742-50. (Pubitemid 30413331)
53. Picker SM, Schneider V, Oustianskaia L, Gathof BS,. Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies. Transfusion 2009; 49: 2311-8.
54. Apelseth TO, Bruserud O, Wentzel-Larsen T, Bakken AM, Bjorsvik S, Hervig T,. In-vitro evaluation of metabolic changes and residual platelet responsiveness in photochemically-treated and gamma-irradiated single-donor platelet concentrates during long-term storage. Transfusion 2007; 47: 657-65.
55. Keuren JF, Cawenberghs S, Heeremans J, de Kort W, Heemskerk JW, Curvers J,. Platelet ADP response deteriorates in synthetic storage media. Transfusion 2006; 46: 204-12. (Pubitemid 43381755)
56. Reesink HW, Panzer S, McQuilten ZK, Wood EM, Marks DC, Wendel S, Trigo F, Biagini S, Olyntho S, Devine DV, Mumford I, Cazenave JP, RasonglÃs P, Garraud O, Richard P, Schooneman F, Vezon G, Al Radwan R, Brand A, Hervig T, Castro E, Lozano M, Navarro L, Puig L, Almazán C, MacLennan S, Cardigan R, Franklin IM, Prowse C,. Pathogen inactivation of platelet concentrates. Vox Sang 2010; 99: 85-95.